Anúncio
Anúncio

JANX

JANX logo

Janux Therapeutics, Inc. Common Stock

13.44
USD
Patrocinado
-0.31
-2.24%
06 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

13.45

+0.01
+0.05%

Relatórios de Lucros JANX

Rácio de surpresa positiva

JANX separação 12 de 18 últimas estimativas.

67%

Próximo Relatório

Data do Próximo Relatório
25 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$170.00K
/
-$0.65
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-98.30%
/
+66.67%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
+80.56%

Janux Therapeutics, Inc. Common Stock earnings per share and revenue

On 06 de nov. de 2025, JANX reported earnings of -0.39 USD per share (EPS) for Q3 25, beating the estimate of -0.62 USD, resulting in a 38.07% surprise. Revenue reached 10.00 milhão, compared to an expected 2.99 milhão, with a 234.77% difference. The market reacted with a -7.61% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 19 analistas forecast an EPS of -0.65 USD, with revenue projected to reach 170.00 mil USD, implying an aumentar of 66.67% EPS, and diminuir of -98.30% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
For Q3 2025, Janux Therapeutics, Inc. Common Stock reported EPS of -$0.39, beating estimates by 38.07%, and revenue of $10.00M, 234.77% above expectations.
The stock price moved down -7.61%, changed from $28.66 before the earnings release to $26.48 the day after.
The next earning report is scheduled for 25 de fev. de 2026.
Based on 19 analistas, Janux Therapeutics, Inc. Common Stock is expected to report EPS of -$0.65 and revenue of $170.00K for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio